Victory Capital Management Inc. Sells 36,608 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Victory Capital Management Inc. lessened its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 17.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 172,879 shares of the company's stock after selling 36,608 shares during the quarter. Victory Capital Management Inc. owned about 0.61% of Krystal Biotech worth $21,447,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its position in Krystal Biotech by 2.5% in the third quarter. Commonwealth Equity Services LLC now owns 4,426 shares of the company's stock worth $513,000 after buying an additional 110 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Krystal Biotech by 1.7% during the third quarter. Bank of New York Mellon Corp now owns 98,220 shares of the company's stock valued at $11,394,000 after purchasing an additional 1,604 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Krystal Biotech by 11.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,487 shares of the company's stock valued at $520,000 after purchasing an additional 452 shares during the period. Strs Ohio raised its holdings in Krystal Biotech by 120.7% during the 3rd quarter. Strs Ohio now owns 6,400 shares of the company's stock worth $742,000 after buying an additional 3,500 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Krystal Biotech by 4.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,515 shares of the company's stock valued at $1,452,000 after buying an additional 566 shares in the last quarter. Institutional investors own 86.29% of the company's stock.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the transaction, the insider now directly owns 1,550,882 shares of the company's stock, valued at approximately $265,138,786.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CAO Kathryn Romano sold 5,000 shares of the business's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total value of $829,400.00. Following the sale, the chief accounting officer now owns 12,936 shares in the company, valued at approximately $2,145,823.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the sale, the insider now owns 1,550,882 shares of the company's stock, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,087 shares of company stock worth $6,210,591. Company insiders own 14.10% of the company's stock.

Krystal Biotech Price Performance

NASDAQ:KRYS traded down $3.98 during midday trading on Friday, reaching $154.76. The stock had a trading volume of 186,317 shares, compared to its average volume of 360,131. The stock has a market capitalization of $4.42 billion, a P/E ratio of 82.76 and a beta of 0.91. The firm's fifty day simple moving average is $168.49 and its 200-day simple moving average is $134.74. Krystal Biotech, Inc. has a 1-year low of $86.03 and a 1-year high of $189.97.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, May 6th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.20 by ($0.17). The company had revenue of $45.25 million during the quarter, compared to analyst estimates of $47.37 million. The firm's quarterly revenue was up 452400.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.76) earnings per share. On average, equities research analysts anticipate that Krystal Biotech, Inc. will post 1.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Citigroup raised their price objective on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a "buy" rating in a research note on Tuesday, February 27th. Stifel Nicolaus reissued a "buy" rating and issued a $204.00 price target (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. HC Wainwright reaffirmed a "buy" rating and set a $200.00 price objective on shares of Krystal Biotech in a research report on Monday. William Blair reiterated an "outperform" rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Finally, Guggenheim boosted their price target on shares of Krystal Biotech from $130.00 to $175.00 and gave the company a "buy" rating in a report on Tuesday, February 27th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $171.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).